Welcome to our dedicated news page for Veracyte (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veracyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veracyte's position in the market.
Rhea-AI Summary
Veracyte, Inc. (VCYT) announced new data presented at the 24th Annual Meeting of the Society of Urologic Oncology, highlighting clinical observations and translational research on the Decipher Prostate Genomic Classifier. The studies support its clinical utility in the treatment and management of prostate cancer, particularly for active surveillance candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) has announced that its Percepta Nasal Swab test has been found to accurately determine lung cancer risk among current and former smokers with lung nodules, potentially avoiding unnecessary invasive procedures and accelerating appropriate treatment. The test is simple, non-invasive, and provides insights to objectively assess lung cancer risk, guiding physicians in determining which patients to work up for lung cancer and which to monitor with imaging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
Rhea-AI Summary
Veracyte, Inc. (VCYT) will present seven posters at the 24th Annual Meeting of the Society of Urologic Oncology, showcasing the clinical performance of its Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. The posters will report data from over 60,000 patients, addressing the ongoing challenge in prostate cancer management. The company aims to provide a more complete understanding of each patient's cancer for personalized care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) Grew Total Revenue to $90.1 million, an Increase of 19%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
-
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announces multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop high-performing molecular tests for decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx NGS instrument, part of Veracyte’s expanded IVD approach. The first tests to be developed are Prosigna Breast Cancer Assay and Percepta Nasal Swab test, aimed at improving diagnostic and treatment decisions for breast cancer and lung nodules. Illumina's NextSeq 550Dx instrument offers validated mid-throughput platform with regulatory approvals in over 60 countries, broadening market access and enabling faster turnaround times for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
-
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announced that CFO Rebecca Chambers will participate in a fireside chat at the Stephens Annual Investment Conference on November 15 at 3:00 p.m. ET. A live webcast will be available on Veracyte's website, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
Rhea-AI Summary
Veracyte, Inc. announces two poster presentations at SITC 2023 showcasing the potential of their tools in immuno-oncology drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
-
Rhea-AI Summary
Veracyte, Inc. to release financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
-
Rhea-AI Summary
Veracyte, Inc. presents new data demonstrating the clinical utility of the Envisia Genomic Classifier for diagnosing interstitial lung diseases (ILDs). The studies show that adding the Envisia Genomic Classifier to the diagnostic process improves the ability to detect usual interstitial pneumonia (UIP), a hallmark of idiopathic pulmonary fibrosis and ILDs that are more likely to progress over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
Rhea-AI Summary
Veracyte, Inc. presents new data at ASTRO Annual Meeting on the value of the Decipher Prostate Genomic Classifier in helping inform treatment decisions for prostate cancer. The study shows that the Decipher Prostate test accurately categorizes risk of patients with high-risk disease. Another study suggests that there is minimal to moderate correlation between gene expression signatures of three commercially available genomic classifiers. The level of evidence supporting each test should drive utilization. The findings reinforce the Decipher Prostate test's performance as a tool to guide therapeutic decisions in prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
Veracyte, Inc.
Nasdaq:VCYT
VCYT Rankings
VCYT Stock Data
1.54B
74.51M
1.15%
97.54%
4.85%
Medical Laboratories
Health Care and Social Assistance
United States of America
SOUTH SAN FRANCISCO
About VCYT
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .